Drugs / Hydrogen
Hydrogen
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07411911 | Mar 2026 → Mar 2028 expected | brain hypoxia - ischemia, perinatal asphyxia | Boston Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05574296 | Mar 2024 → Mar 2027 expected | cardiac arrest | Boston Children's Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05196295 | Jan → Jul 2022 | autoimmune disease, metabolic disease | HoHo Biotech | Unknown | No outcome recorded |
| Phase 1 | NCT05116215 | Aug 2021 → Aug 2022 | autoimmune disease | HoHo Biotech | Unknown | No outcome recorded |
| Phase 1 | NCT04633980 | Dec 2020 → Jun 2022 | COVID-19 | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 1 | NCT04046211 | Oct 2020 → May 2021 | — | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04175301 | Oct 2019 → Sep 2026 expected | malignant glioma | Stony Brook University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02918188 | Jan 2016 → Jan 2026 overdue | chronic graft versus host disease | Navy General Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03971617 | May 2019 → Apr 2021 | Parkinson disease | Stony Brook University | Terminated | No outcome recorded |
| Phase 2/3 | NCT03320018 | Aug 2017 → Aug 2019 | ischemic stroke | Stony Brook University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydrogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05574296 ↗ |
| Known as | H2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633980 ↗ |
| Known as | Hydrogen Gas | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07411911 ↗ |
| Known as | molecular dihydrogen | “This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19.” PMID 39016593 ↗ Jul 2024 |
| Known as | molecular hydrogen | “This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with...” NCT03971617 ↗ |
| Action | Inhibit | “H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation” PMID 39016593 ↗ Jul 2024 |
| Modality | Other / unclassified | “molecular dihydrogen (H2) inhalation” PMID 39016593 ↗ Jul 2024 |
| Route | Oral | “Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)” NCT02918188 ↗ |